GREM1 and diabetes mellitus: These data demonstrate that gremlin siRNA plasmid delivery significantly inhibited glomerular and tubular hypertrophy in diabetic kidneys from week 1 to week 12, alleviated proteinuria and displayed a protective effect on renal function at week 12.